iFGF23 Plasma Levels in Transfusion-Dependent β-Thalassemia: Insights into Bone and Iron Metabolism
Journal of Clinical Medicine · 08.03.2025 · 14 (6) · 1834
DOI: 10.3390/jcm14061834 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.03.2025. Verfasst von Alberto Gobbo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Ferrara.
Abstract (Originalsprache)
Background
FGF23 is a phosphate homeostasis regulator; the literature suggests a link between FGF23, iron homeostasis and erythropoiesis. Little is known about the FGF23 level variations in β-thalassemia (βT), which is characterized by ineffective erythropoiesis and iron overload. Our cross-sectional study aims to evaluate the iFGF23 level variations in a large cohort of βT patients considering their bone mineral densities (BMDs) and iron loads.
Methods
Clinical, biochemical and radiological data were collected from 213 transfusion-dependent βT (TDT) adults referring to the Regional HUB Centre for Thalassaemia and Haemoglobinopathies in Ferrara, Italy. The iFGF23 levels in the TDT patients were compared to the general population’s reference range. The BMDs and hearth and liver iron deposits were assessed with DEXA scans and MRI, respectively.
Results
The iFGF23 distribution in the TDT subjects is significantly different from that of the general population. The iFGF23 levels are positively correlated with the age at transfusion initiation and calcium and phosphate levels and are negatively correlated with the osteocalcin plasma levels. Patients treated with deferasirox had lower iFGF23 levels than those treated with other chelators. The iFGF23 levels are not correlated with the BMD or iron status.
Conclusions
These findings provide insights into the relationship between the iFGF23 and bone and iron metabolism in TDT patients. Further studies are needed to explore its potential clinical relevance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy.
- Department of Specialized Medicine, Day Hospital of Thalassemia and Hemoglobinopathies, Azienda Ospedaliero Universitaria S. Anna, 44124 Ferrara, Italy.
- Unit of Endocrinology and Metabolic Diseases, Department of Specialty Medicines, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy.
- Radiology Unit, Azienda Ospedaliero Universitaria di Ferrara, 44124 Ferrara, Italy.
ORCID-Profile: Alberto Gobbo, Filomena Longo, Martina Verrienti, Gianluca Marzi, Martina Culcasi, Alberto Cossu, Maria Chiara Zatelli
Förderung
- University of Ferrara
Zitieren
APA
Gobbo, A., Longo, F., Cattaneo, C. A., Verrienti, M., Marzi, G., Chamekh, F., Culcasi, M., Cossu, A., Zatelli, M. C., & Ambrosio, M. R. (2025). iFGF23 Plasma Levels in Transfusion-Dependent β-Thalassemia: Insights into Bone and Iron Metabolism. Journal of Clinical Medicine, 14(6), 1834. https://doi.org/10.3390/jcm14061834
Vancouver
Gobbo A, Longo F, Cattaneo CA, Verrienti M, Marzi G, Chamekh F, et al. iFGF23 Plasma Levels in Transfusion-Dependent β-Thalassemia: Insights into Bone and Iron Metabolism. Journal of Clinical Medicine. 2025;14(6):1834. doi:10.3390/jcm14061834
BibTeX
@article{Gobbo2025,
author = {Gobbo, Alberto and Longo, Filomena and Cattaneo, Camilla Alice and Verrienti, Martina and Marzi, Gianluca and Chamekh, Fatima and Culcasi, Martina and Cossu, Alberto and Zatelli, Maria Chiara and Ambrosio, Maria Rosaria},
title = {iFGF23 Plasma Levels in Transfusion-Dependent β-Thalassemia: Insights into Bone and Iron Metabolism},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {6},
pages = {1834},
doi = {10.3390/jcm14061834}
}
EUVIMED